| Transgender femalesa | |
| Estrogen | |
| Oral | |
| Estradiol | 2.0–6.0 mg/d |
| Transdermal | |
| Estradiol transdermal patch | 0.025–0.2 mg/d |
| (New patch placed every 3–5 d) | |
| Parenteral | |
| Estradiol valerate or cypionate | 5–30 mg IM every 2 wk |
| 2–10 mg IM every week | |
| Anti-androgens | |
| Spironolactone | 100–300 mg/d |
| Cyproterone acetateb | 25–50 mg/d |
| GnRH agonist | 3.75 mg SQ (SC) monthly |
| 11.25 mg SQ (SC) 3-monthly | |
| Transgender males | |
| Testosterone | |
| Parenteral testosterone | |
| Testosterone enanthate or cypionate | 100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week |
| Testosterone undecanoatec | 1000 mg every 12 wk |
| Transdermal testosterone | |
| Testosterone gel 1.6%d | 50–100 mg/d |
| Testosterone transdermal patch | 2.5–7.5 mg/d |
| Transgender femalesa | |
| Estrogen | |
| Oral | |
| Estradiol | 2.0–6.0 mg/d |
| Transdermal | |
| Estradiol transdermal patch | 0.025–0.2 mg/d |
| (New patch placed every 3–5 d) | |
| Parenteral | |
| Estradiol valerate or cypionate | 5–30 mg IM every 2 wk |
| 2–10 mg IM every week | |
| Anti-androgens | |
| Spironolactone | 100–300 mg/d |
| Cyproterone acetateb | 25–50 mg/d |
| GnRH agonist | 3.75 mg SQ (SC) monthly |
| 11.25 mg SQ (SC) 3-monthly | |
| Transgender males | |
| Testosterone | |
| Parenteral testosterone | |
| Testosterone enanthate or cypionate | 100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week |
| Testosterone undecanoatec | 1000 mg every 12 wk |
| Transdermal testosterone | |
| Testosterone gel 1.6%d | 50–100 mg/d |
| Testosterone transdermal patch | 2.5–7.5 mg/d |
Abbreviations: IM, intramuscularly; SQ, sequentially; SC, subcutaneously.
Estrogens used with or without antiandrogens or GnRH agonist.
Not available in the United States.
One thousand milligrams initially followed by an injection at 6 wk then at 12-wk intervals.
Avoid cutaneous transfer to other individuals.
| Transgender femalesa | |
| Estrogen | |
| Oral | |
| Estradiol | 2.0–6.0 mg/d |
| Transdermal | |
| Estradiol transdermal patch | 0.025–0.2 mg/d |
| (New patch placed every 3–5 d) | |
| Parenteral | |
| Estradiol valerate or cypionate | 5–30 mg IM every 2 wk |
| 2–10 mg IM every week | |
| Anti-androgens | |
| Spironolactone | 100–300 mg/d |
| Cyproterone acetateb | 25–50 mg/d |
| GnRH agonist | 3.75 mg SQ (SC) monthly |
| 11.25 mg SQ (SC) 3-monthly | |
| Transgender males | |
| Testosterone | |
| Parenteral testosterone | |
| Testosterone enanthate or cypionate | 100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week |
| Testosterone undecanoatec | 1000 mg every 12 wk |
| Transdermal testosterone | |
| Testosterone gel 1.6%d | 50–100 mg/d |
| Testosterone transdermal patch | 2.5–7.5 mg/d |
| Transgender femalesa | |
| Estrogen | |
| Oral | |
| Estradiol | 2.0–6.0 mg/d |
| Transdermal | |
| Estradiol transdermal patch | 0.025–0.2 mg/d |
| (New patch placed every 3–5 d) | |
| Parenteral | |
| Estradiol valerate or cypionate | 5–30 mg IM every 2 wk |
| 2–10 mg IM every week | |
| Anti-androgens | |
| Spironolactone | 100–300 mg/d |
| Cyproterone acetateb | 25–50 mg/d |
| GnRH agonist | 3.75 mg SQ (SC) monthly |
| 11.25 mg SQ (SC) 3-monthly | |
| Transgender males | |
| Testosterone | |
| Parenteral testosterone | |
| Testosterone enanthate or cypionate | 100–200 mg SQ (IM) every 2 wk or SQ (SC) 50% per week |
| Testosterone undecanoatec | 1000 mg every 12 wk |
| Transdermal testosterone | |
| Testosterone gel 1.6%d | 50–100 mg/d |
| Testosterone transdermal patch | 2.5–7.5 mg/d |
Abbreviations: IM, intramuscularly; SQ, sequentially; SC, subcutaneously.
Estrogens used with or without antiandrogens or GnRH agonist.
Not available in the United States.
One thousand milligrams initially followed by an injection at 6 wk then at 12-wk intervals.
Avoid cutaneous transfer to other individuals.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
